Vaccination Report – 15 February 2022

1. Vaccine Implementation

- WHO's Emergency Use Listing(EUL) Vaccines (Last Updated 23 Dec 2021)
- •

	Manufacturer	Name of Vaccine	NRA of Record	Vaccine type
1	Pfizer-BioNTech (US)			mRNA
2	AstraZeneca (UK)	eneca ChAdOx1 EMA/ (AZS1222 Vaxzevria) Japan MHLW/PMDA/ Australia TGA		Non ReplicatingViral vector
3	Serum Institute of India (India)	Covishield (ChAdOx1_nCoV-19)	DCGI	Non Replicating Viral Vector
4	Johnson &Johnson (US)	Ad26.CoV2.S	EMA	Non ReplicatingViral vector
5	Moderna (US)	$mRNA_12/3$ $EMA/USEI$		mRNA
6	Sinopharm Beijing (China)	BBIBP-CorV	NMPA	Inactivated virus (Vero Cells)
7	Sinovac (China)	SARS-CoV-2 Vaccine	NMPA	Inactivated virus (Vero Cell)
8	Bharat Biotech (India) SARS-CoV-2 Vaccine, Inactivated (Vero Cell)/ COVAXIN DCG		DCGI	Whole-Virion Inactivated (Vero Cell)
9	Serum Institute of India (India)	NVX-CoV2373/Covovax	DCGI	Protein Subunit
10	NOVAVAX (US)	NVX-CoV2373/Covovax	EMA	Protein Subunit

• **33** Vaccines Approved by at Least One Country

Vaccine Type	mRNA	Non Replicating Viral vector	Inactivated virus	Protein Subunit	DNA	Total
In Use	3	6	10	13	1	33

Source: <u>https://covid19.trackvaccines.org/vaccines/</u> (Last Updated 14 Feb 2022)

 Vaccination against COVID-19 has now started in 218 locations (Source: <u>Our World in Data</u>. Last Updated 14 Feb, 2022)


Location	Doses given	Fully vaccinated (% of population)	At least 1 dose (% of population)
Worldwide	10.42 billion	4.27 billion (54.16%)	4.88 billion (61.93%)

About this data:

a: This data changes rapidly and might not reflect doses still being reported. It may differ from other sites & sources.

b: Where data for full vaccinations is available, it shows how many people have received at least 1 dose and how many people have been fully vaccinated (which may require more than 1 dose). Where data for full vaccinations isn't available, the data shows the total number of vaccine doses given to people. Since some vaccines require more than 1 dose, the number of fully vaccinated people is likely lower.


c: It only has full vaccination totals in some locations.




Source: Official data collated by Our World in Data Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries. CC BY

Our Worl in Data


Share of people who completed the initial COVID-19 vaccination protocol, Feb 14, 2022 Total number of people ed all doses prescribed by the initial vaccination protocol, divided by the total population of the country.



Source: Official data collated by Our World in Data – Last updated 15 February 2022, 08:30 (London time) Note: Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries. OurWorldInData.org/coronavirus • CC BY



Source: Oxford COVID-19 Government Response Tracker, Blavatnik School of Government, University of Oxford – Last updated 15 February 2022, 10:50 (London time) OurWorldInData.org/coronavirus • CC BY



2. Vaccine effectiveness against symptomatic infection for Alpha and Delta variants

Vaccine Status	Vaccine Effectiveness		
	Alpha	Delta	Omicron
1 Dose (BNT162b2 or ChAdOx1 nCoV-19)	48.7% (95%Cl: 45.5-51.7%) ¹ 66%(BNT162b2) ⁴ 64% (ChAdOx1) ⁴	30.7% (95%Cl: 25.2-35.7%) ¹ 56%(BNT162b2) ⁴ 67%(ChAdOx1) ⁴ 82% (95% Cl:73- 91%) ⁷	
1 Dose (mRNA-1273)	83% ⁴	72% ⁴	
1 Dose(Sinopharm or Sinovac)	Unknown	13.8%,(95%CI: -60.2-54.8%) ³	

2 Doses (BNT162b2)	93.7% (95%CI: 91.6-95.3) ¹ 76% (95%CI: 69-81%) ² 89% ⁴	88% (95%CI: 85.3-90.1%) ¹ 42% (95% CI: 13-62%) ² 87% ⁴ 93%(95% CI: 88-97%/12-18Y) ⁵ 93% (95% CI: 88-97%) ⁷	50% (95% Cl: 35%–62%) ⁸
2 Doses (ChAdOx1 nCoV-19)	74.5% (95%CI: 68.4-79.4%) ¹	67.0% (95%Cl: 61.3-71.8%) ¹	
2 Doses (mRNA-1273)	86%, (95%CI: 81-90.6%) ²	76%, (95% Cl: 58-87%) ²	30.4% (95% Cl: 5.0%-49.0%) ⁹
2 Doses(Sinopharm or Sinovac)	Unknown	59.0%, (95%Cl: 16.0-81.6%) ³	
3 Doses (BNT162b2)	Unknown	95.33% (SD 6.44) ⁶	
3 Doses(mRNA-1273)			62.5% (95% CI: 56.2%-67.9%) ⁹

References:

- 1) Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
- 2) <u>Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of</u> <u>Alpha and Delta variant prevalence</u>
- 3) Efficacy of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study
- 4) Effectiveness of COVID-19 vaccines against variants of concern in Ontario, Canada
- 5) Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
- 6) <u>A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses</u> of CoronaVac
- 7) Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
- 8) Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
- 9) Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

3. Latest Relevant Articles

- Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study
- <u>Coronavirus Disease 2019 (COVID-19) Vaccine Boosting in Persons Already</u> <u>Protected by Natural or Vaccine-Induced Immunity</u>
- Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines
 against symptomatic SARS-CoV-2 Omicron infection in Qatar
- Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

4. Other Information

<u>New CDC Studies: COVID-19 boosters remain safe, continue to offer high levels</u>
 <u>of protection against severe disease over time and during Omicron and Delta</u>
 <u>waves</u>

• <u>The Australian Government announced changes to the definition of fully</u> vaccinated against COVID-19 on 10 February 2022.